Compare Regeneron Pharmaceuticals Inc (REGN) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Ralph Lauren Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Ralph Lauren Corp trades at $387.44 (market cap $22.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.1× Ralph Lauren Corp's market cap, and Ralph Lauren Corp pays the higher dividend (0.98%). Which is the better fit depends on your goals.
| REGN | RL | |
|---|---|---|
Market Cap | $70.79B | $22.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $812.27 | $414.25 |
52-Week Low | $545.46 | $283.34 |
Enterprise Value | $64.74B | $23.73B |
Dividend Yield | 0.56% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Ralph Lauren (RL) trades at $382.93, up 0.65% today, with strong fundamentals including 11.6% net margin and 34.66% ROE. Recent earnings beats and a $1.00 dividend signal financial health, though technical indicators show bearish momentum near resistance at $383. Revenue growth to $7.08B in 2025 and a $445.71 analyst target suggest upside potential.
The stock offers growth through premium branding and digital expansion, but faces risks from consumer discretionary weakness and high valuation multiples. Analyst consensus is strongly bullish (66% buy ratings), yet technical pressure and macroeconomic sensitivity warrant caution for near-term entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
